PURPOSE: Belotecan (Camtobell, Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin derivative anti-tumor agent that belongs to the topoisomerase inhibitors. The aim of this phase II study was to evaluate the efficacy and safety of single agent belotecan in patients with extensive stage small cell lung cancer (SCLC).
METHODS: Patients with previously untreated extensive stage SCLC were entered into the study. Belotecan was given by daily intravenous infusion at 0.5 mg/m2/day for 5 consecutive days, every 3 weeks.
RESULTS: 62 patients were enrolled and 47 patients were eligible for the response in this study. 1 complete response and 30 partial responses were achieved, giving an overall response rate of 65.9%. Grade 3/4 neutropenia occurred in 70.5% of patients and 29.4% of thrombocytopenia without significant other toxicity.
CONCLUSION: The results suggest that belotecan is active and well tolerable in patients with extensive disease SCLC as first line treatment.
CLINICAL IMPLICATIONS: This study was to evaluate the response and toxicity of new anti-cancer drug developed in Korea.
DISCLOSURE: Seung Joon Kim, No Financial Disclosure Information; No Product/Research Disclosure Information